Assessment of Osteoprotegerin and Receptor Activator of Nf-Κb Ligand in Malaysian Male Patients with Chronic Obstructive Pulmonary Disease : A Cross-Sectional Study
Background: Limited information exists regarding the pathophysiological interactions between osteoporosis and chronic obstructive pulmonary disease (COPD). Objective: To study the association of Osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-Β ligand (RANKL) in male COPD patie...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Permanyer
2024
|
| Subjects: | |
| Online Access: | http://ir.unimas.my/id/eprint/47026/1/Assessment%20of%20Osteoprotegerin.pdf http://ir.unimas.my/id/eprint/47026/ https://www.clinicalandtranslationalinvestigation.com/frame_esp.php?id=517 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background: Limited information exists regarding the pathophysiological interactions between osteoporosis and chronic obstructive pulmonary disease (COPD). Objective: To study the association of Osteoprotegerin (OPG) and receptor activator of
nuclear factor kappa-Β ligand (RANKL) in male COPD patients. Methods: An observational clinical study was conducted at
Penang General Hospital in Malaysia. Participants were divided into three groups: COPD patients with osteoporosis, COPD patients
without osteoporosis, and healthy participants of the same age groups. Serum OPG (sOPG) and RANKL (sRANKL) levels were
investigated. Results: The mean age of COPD patients was 64.10 ± 10.04 years. COPD patients had lower body mass index
(23.22 ± 6.43) than healthy participants (27.32 ± 6.80). The T-score was significantly lower among COPD patients than
healthy participants (p = 0.018). The sOPG concentration among healthy participants was significantly higher (361.90 ±
29.10 pg/mL, p < 0.001) than in the other groups, while the sRANKL concentration was not significantly different. The serum
OPG/RANKL concentration was markedly higher in the control group than in the COPD patient group (p < 0.05). The COPD
patients with osteoporosis had significantly lower pulmonary parameters (forced expiratory volume in the first [FEV]1% and
FEV1/[forced vital capacity] (FVC), p < 0.01) and more dyspnea (modified medical research council = 2.60 ± 0.78 versus 1.90 ±
0.70, p < 0.01) than did the patients without osteoporosis. Furthermore, patients with severe COPD had a 3 times greater risk
of developing osteoporosis (OR = 2.997 [95% CI = 2.181, 4.118], p < 0.001), while spirometric parameters had a significant
inverse relationship with osteoporosis (FEV1% OR = 0.970, [95% CI = 0.954, 0.986], p = 0.001; FEV1/FVC OR = 0.984, (95%
CI = 0.970, 0.999], p = 0.035). Conclusion: The study concluded that COPD patients had lower sOPG levels, leading to decreased
OPG/RANKL ratio and faster bone resorption. Low bone mineral density was associated with more severe COPD. (REV INVEST
CLIN. 2024;76(6):262-73) |
|---|